Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2020

Open Access 01-12-2020 | Heart Failure | Original investigation

Cardiac resynchronization therapy and its effects in patients with type 2 DIAbetes mellitus OPTimized in automatic vs. echo guided approach. Data from the DIA-OPTA investigators

Authors: Celestino Sardu, Pasquale Paolisso, Valentino Ducceschi, Matteo Santamaria, Cosimo Sacra, Massimo Massetti, Antonio Ruocco, Raffaele Marfella

Published in: Cardiovascular Diabetology | Issue 1/2020

Login to get access

Abstract

Objectives

To evaluate the effects of cardiac resynchronization therapy (CRTd) in patients with type 2 diabetes mellitus (T2DM) optimized via automatic vs. echocardiography-guided approach.

Background

The suboptimal atrio-ventricular (AV) and inter-ventricular (VV) delays optimization reduces CRTd response. Therefore, we hypothesized that automatic CRTd optimization might improve clinical outcomes in T2DM patients.

Methods

We designed a prospective, multicenter study to recruit, from October 2016 to June 2019, 191 consecutive failing heart patients with T2DM, and candidate to receive a CRTd. Study outcomes were CRTd responders rate, hospitalizations for heart failure (HF) worsening, cardiac deaths and all cause of deaths in T2DM patients treated with CRTd and randomly optimized via automatic (n 93) vs. echocardiography-guided (n 98) approach at 12 months of follow-up.

Results

We had a significant difference in the rate of CRTd responders (68 (73.1%) vs. 58 (59.2%), p 0.038), and hospitalizations for HF worsening (12 (16.1%) vs. 22 (22.4%), p 0.030) in automatic vs. echocardiography-guided group of patients. At multivariate Cox regression analysis, the automatic guided approach (3.636 [1.271–10.399], CI 95%, p 0.016) and baseline highest values of atrium pressure (automatic SonR values, 2.863 [1.537–6.231], CI 95%, p 0.006) predicted rate of CRTd responders. In automatic group, we had significant difference in SonR values comparing the rate of CRTd responders vs. non responders (1.24 ± 0.72 g vs. 0.58 ± 0.46 g (follow-up), p 0.001), the rate of hospitalizations for HF worsening events (0.48 ± 0.29 g vs. 1.18 ± 0.43 g, p 0.001), and the rate of cardiac deaths ( 1.13 ± 0.72 g vs. 0.65 ± 0.69 g, p 0.047).

Conclusions

Automatic optimization increased CRTd responders rate, and reduced hospitalizations for HF worsening. Intriguingly, automatic CRTd and highest baseline values of SonR could be predictive of CRTd responders. Notably, there was a significant difference in SonR values for CRTd responders vs. non responders, and about hospitalizations for HF worsening and cardiac deaths.
Clinical trial ClinicalTrials.gov Identifier NCT04547244.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sardu C, Barbieri M, Santamaria M, et al. Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes. Cardiovasc Diabetol. 2017;16(1):75.CrossRef Sardu C, Barbieri M, Santamaria M, et al. Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes. Cardiovasc Diabetol. 2017;16(1):75.CrossRef
2.
go back to reference Cleland JG, Daubert JC, Erdmann E, et al. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539–49.CrossRef Cleland JG, Daubert JC, Erdmann E, et al. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539–49.CrossRef
3.
go back to reference Auricchio A, Prinzen FW. Non-responders to cardiac resynchronization therapy: the magnitude of the problem and the issues. Circ J. 2011;75:521–7.CrossRef Auricchio A, Prinzen FW. Non-responders to cardiac resynchronization therapy: the magnitude of the problem and the issues. Circ J. 2011;75:521–7.CrossRef
4.
go back to reference Daubert C, Behar N, Raphael PM, Mabo P, Leclercq C. Avoiding non-responders to cardiac resynchronization therapy: a practical guide. Eur Heart J. 2017;38:1463–72.PubMed Daubert C, Behar N, Raphael PM, Mabo P, Leclercq C. Avoiding non-responders to cardiac resynchronization therapy: a practical guide. Eur Heart J. 2017;38:1463–72.PubMed
5.
go back to reference Cuoco FA, Gold MR. Optimization of cardiac resynchronization therapy: importance of programmed parameters. J Cardiovasc Electrophysiol. 2012;23:110–8.CrossRef Cuoco FA, Gold MR. Optimization of cardiac resynchronization therapy: importance of programmed parameters. J Cardiovasc Electrophysiol. 2012;23:110–8.CrossRef
6.
go back to reference Sardu C, Paolisso P, Sacra C, et al. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate. Cardiovasc Diabetol. 2018;17(1):137.CrossRef Sardu C, Paolisso P, Sacra C, et al. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate. Cardiovasc Diabetol. 2018;17(1):137.CrossRef
7.
go back to reference Niazi I, Baker J, Corbisiero R, et al. MPP Investigators. Safety and efficacy of multipoint pacing in cardiac resynchronization therapy: the multipoint pacing trial. JACC Clin Electrophysiol. 2017;3(13):1510–8.CrossRef Niazi I, Baker J, Corbisiero R, et al. MPP Investigators. Safety and efficacy of multipoint pacing in cardiac resynchronization therapy: the multipoint pacing trial. JACC Clin Electrophysiol. 2017;3(13):1510–8.CrossRef
8.
go back to reference Ritter P, Delnoy PPH, Padeletti L, et al. A randomized pilot study of optimization of cardiac resynchronization therapy in sinus rhythm patients using a peak endocardial acceleration sensor vs standard methods. Europace. 2012a;14:1324–33.CrossRef Ritter P, Delnoy PPH, Padeletti L, et al. A randomized pilot study of optimization of cardiac resynchronization therapy in sinus rhythm patients using a peak endocardial acceleration sensor vs standard methods. Europace. 2012a;14:1324–33.CrossRef
9.
go back to reference Kamdar R, Frain E, Warburton F, et al. A prospective comparison of echocardiography and device algorithms for atrioventricular and interventricular interval optimization in cardiac resynchronization therapy. EP Europace. 2009;12:84–91.CrossRef Kamdar R, Frain E, Warburton F, et al. A prospective comparison of echocardiography and device algorithms for atrioventricular and interventricular interval optimization in cardiac resynchronization therapy. EP Europace. 2009;12:84–91.CrossRef
10.
go back to reference Brugada J, Delnoy PD, Brachmann J, et al. for the RESPOND CRT Investigators. Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial. European Heart J. 2017;38:730–8. Brugada J, Delnoy PD, Brachmann J, et al. for the RESPOND CRT Investigators. Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial. European Heart J. 2017;38:730–8.
11.
go back to reference Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009;32(6):1119–31. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009;32(6):1119–31.
12.
go back to reference Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am CollCardiol. 2017;70(6):776–803.CrossRef Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am CollCardiol. 2017;70(6):776–803.CrossRef
13.
go back to reference Sardu C, Santamaria M, Funaro S, Sacra C, Barbieri M, Paolisso P, Marfella R, Paolisso G, Rizzo MR. Cardiac electrophysiological alterations and clinical response in cardiac resynchronization therapy with a defibrillator treated patients affected by metabolic syndrome. Medicine (Baltimore). 2017;96(14):e6558.CrossRef Sardu C, Santamaria M, Funaro S, Sacra C, Barbieri M, Paolisso P, Marfella R, Paolisso G, Rizzo MR. Cardiac electrophysiological alterations and clinical response in cardiac resynchronization therapy with a defibrillator treated patients affected by metabolic syndrome. Medicine (Baltimore). 2017;96(14):e6558.CrossRef
14.
go back to reference Ritter P, Delnoy PPH, Padeletti L, et al. A randomized pilot study of optimization of cardiac resynchronization therapy in sinus rhythm patients using a peak endocardial acceleration sensor vs. standard methods. Europace. 2012b;14:1324–33.CrossRef Ritter P, Delnoy PPH, Padeletti L, et al. A randomized pilot study of optimization of cardiac resynchronization therapy in sinus rhythm patients using a peak endocardial acceleration sensor vs. standard methods. Europace. 2012b;14:1324–33.CrossRef
15.
go back to reference Gorcsan J III, Abraham T, Agler DA, et al. Echocardiography for cardiac resynchronization therapy: recommendations for performance and reporting—a report from the American Society of Echocardiography Dyssynchrony Writing Group endorsed by the Heart Rhythm Society. J Am Soc Echocardiogr. 2008;21:191–213.CrossRef Gorcsan J III, Abraham T, Agler DA, et al. Echocardiography for cardiac resynchronization therapy: recommendations for performance and reporting—a report from the American Society of Echocardiography Dyssynchrony Writing Group endorsed by the Heart Rhythm Society. J Am Soc Echocardiogr. 2008;21:191–213.CrossRef
16.
go back to reference Kerlan JE, Sawhney NS, Waggoner AD, et al. Prospective comparison of echocardiographic atrioventricular delay optimization methods for cardiac resynchronization therapy. Heart Rhythm. 2006a;3:148–54.CrossRef Kerlan JE, Sawhney NS, Waggoner AD, et al. Prospective comparison of echocardiographic atrioventricular delay optimization methods for cardiac resynchronization therapy. Heart Rhythm. 2006a;3:148–54.CrossRef
17.
go back to reference Petretta M, Colao A, Sardu C, et al. NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Horm IGF Res. 2007;17(4):288–96.CrossRef Petretta M, Colao A, Sardu C, et al. NT-proBNP, IGF-I and survival in patients with chronic heart failure. Growth Horm IGF Res. 2007;17(4):288–96.CrossRef
18.
go back to reference Sardu C, Barbieri M, Rizzo MR, Paolisso P, Paolisso G, Marfella R. Cardiac resynchronization therapy outcomes in Type 2 diabetic patients: role of MicroRNA changes. J Diabetes Res. 2016;2016:7292564.CrossRef Sardu C, Barbieri M, Rizzo MR, Paolisso P, Paolisso G, Marfella R. Cardiac resynchronization therapy outcomes in Type 2 diabetic patients: role of MicroRNA changes. J Diabetes Res. 2016;2016:7292564.CrossRef
19.
go back to reference Marfella R, Di Filippo C, Potenza N, et al. Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders. Eur J Heart Fail. 2013;15(11):1277–88.CrossRef Marfella R, Di Filippo C, Potenza N, et al. Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders. Eur J Heart Fail. 2013;15(11):1277–88.CrossRef
20.
go back to reference Sardu C, Marfella R, Santulli G, Paolisso G. Functional role of miRNA in cardiac resynchronization therapy. Pharmacogenomics. 2014;15(8):1159–68.CrossRef Sardu C, Marfella R, Santulli G, Paolisso G. Functional role of miRNA in cardiac resynchronization therapy. Pharmacogenomics. 2014;15(8):1159–68.CrossRef
21.
go back to reference Sardu C, Santamaria M, Rizzo MR, et al. Telemonitoring in heart failure patients treated by cardiac resynchronisation therapy with defibrillator (CRT-D): the TELECART Study. Int J Clin Pract. 2016;70(7):569–76.CrossRef Sardu C, Santamaria M, Rizzo MR, et al. Telemonitoring in heart failure patients treated by cardiac resynchronisation therapy with defibrillator (CRT-D): the TELECART Study. Int J Clin Pract. 2016;70(7):569–76.CrossRef
Metadata
Title
Cardiac resynchronization therapy and its effects in patients with type 2 DIAbetes mellitus OPTimized in automatic vs. echo guided approach. Data from the DIA-OPTA investigators
Authors
Celestino Sardu
Pasquale Paolisso
Valentino Ducceschi
Matteo Santamaria
Cosimo Sacra
Massimo Massetti
Antonio Ruocco
Raffaele Marfella
Publication date
01-12-2020

Other articles of this Issue 1/2020

Cardiovascular Diabetology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine